Key Performance
More- Earnings Score: 82
- Momentum Score: 91
- True Yield: N/A
- Financial Health Score: 55
%20scale(1,1)}%2025%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.943161px,19.954806px)%20scale(1,1)}}%20%23ewMkZ6d8Hun3_ts%20{animation:%20ewMkZ6d8Hun3_ts__ts%204000ms%20linear%20infinite%20normal%20forwards}@keyframes%20ewMkZ6d8Hun3_ts__ts%20{%200%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}%2025%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%2050%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.7,0.7)}%2075%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(0.85,0.85)}%20100%25%20{transform:%20translate(24.9787px,20.012362px)%20scale(1,1)}}%20]]%3e%3c/style%3e%3cdefs%3e%3clinearGradient%20id='ewMkZ6d8Hun2-fill'%20x1='12.5'%20y1='23.5001'%20x2='-0.868518'%20y2='16.4047'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun2-fill-0'%20offset='0%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun2-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3clinearGradient%20id='ewMkZ6d8Hun3-fill'%20x1='31.5059'%20y1='27.1026'%20x2='10.2884'%20y2='14.9373'%20spreadMethod='pad'%20gradientUnits='userSpaceOnUse'%20gradientTransform='translate(0%200)'%3e%3cstop%20id='ewMkZ6d8Hun3-fill-0'%20offset='4.7%25'%20stop-color='%23FF2F00'/%3e%3cstop%20id='ewMkZ6d8Hun3-fill-1'%20offset='100%25'%20stop-color='%23FF9100'/%3e%3c/linearGradient%3e%3c/defs%3e%3cg%20id='ewMkZ6d8Hun2_ts'%20transform='translate(24.943161,19.954806)%20scale(1,1)'%3e%3cpath%20d='M14.8466,29.2814c0,0-14.408088-4.6983-12.05895-19.79995c0,0,1.50345,4.85085,4.13448,5.30845s-2.03592,4.6373,7.92447,14.4915Z'%20transform='translate(-24.943161,-19.954806)'%20fill='url(%23ewMkZ6d8Hun2-fill)'/%3e%3c/g%3e%3cg%20id='ewMkZ6d8Hun3_ts'%20transform='translate(24.9787,20.012362)%20scale(1,1)'%3e%3cpath%20d='M37.4922,21.9282l4.0719.244v-12.81353C31.0713,3.28748,17.7595,7.6502,17.7595,7.6502c.3445-4.51526-3.5707-5.52204-3.5707-5.52204c2.5371,1.52542.3132,6.22373.3132,6.22373C13.0299,0.084092,0,1.02986,0,1.02986C8.92672,4.35528,6.70287,7.98579,6.8908,16.6197c.18794,8.6034,8.3943,12.9966,8.3943,12.9966l-6.60895-.2441v13.2407c0,0,5.48135,2.3797,13.68765,3.1729v-22.3017h-4.4477c-1.0023,0-1.942-.8237-1.942-1.8v-5.7356c0-.9763.9397-1.8,1.942-1.8h4.4477v-1.3424h5.0115v1.3424h5.0115c1.0023,0,1.848.7932,1.848,1.8v5.7356c0,.9763-.8144,1.8-1.848,1.8h-5.0115v22.5153h.2819c11.1192-.0611,15.9428-7.3221,16.256-13.3017.4698-7.7492-6.421-10.7695-6.421-10.7695Z'%20transform='translate(-24.9787,-20.012361)'%20fill='url(%23ewMkZ6d8Hun3-fill)'/%3e%3c/g%3e%3c/svg%3e)
Latest Research & News
IRADIMED's CEO Is Selling Steadily — The Plan, Not the Stock, Is Driving It
IRADIMED CEO Roger E. Susi sold 7,500 shares indirectly through a trust for approximately $691,000 as part of a systematic Rule 10b5-1 plan. The sale represents routine liquidation rather than a negative signal, with the stock up 60.89% over the past year. The key investment variable is the adoption of the company's new infusion pump, with meaningful data expected by mid-2027.
06/02/2026, 8:09 AM • The Motley Fool
Iradimed's CEO Dumped 7,500 Shares. Here's What That Means for Investors.
Iradimed CEO Roger Susi sold 7,500 shares worth ~$694,125 on April 20-21, 2026, as part of a Rule 10b5-1 trading plan adopted in November 2025. The sale is not concerning as it follows a systematic pattern and Susi retains over 4 million shares. Iradimed's strong business performance—with 2025 sales up 14% to $83.8M and net income reaching $22.5M—has driven the stock up 78% over one year, though the elevated forward P/E of 42 suggests waiting for a price dip before buying.
04/28/2026, 10:16 AM • The Motley Fool
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
IRADIMED CORPORATION announced its participation in the 38th Annual Roth Conference on March 22 and 24, 2026, at the Ritz-Carlton in Laguna Niguel, CA. CEO Roger Susi and CFO Jack Glenn will host one-on-one meetings with investors. The company is a leader in MRI-compatible medical devices, including its patented MRidium® IV infusion pump system and 3880 patient vital signs monitoring system.
03/16/2026, 2:00 PM • GlobeNewswire
Why Iradimed Stock Soared Today
Iradimed Corporation's stock surged 9.26% after reporting its 18th consecutive quarter of record revenue at $22.7 million (up 17% YoY) and beating adjusted net income estimates at $0.54 per share versus $0.48 expected. The medical device maker, which specializes in MRI-compatible infusion pump systems, launched a new product and raised its quarterly dividend from $0.17 to $0.20 per share. The company provided 2026 guidance of $91-96 million in revenue and $2.06-2.21 adjusted net income per share.
02/10/2026, 5:12 PM • The Motley Fool
Peers
Statistics
MoreInformation as of 06/22/2026
Company Profile
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. The company serves hospitals, acute care facilities, and outpatient imaging centers. It sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors in the United States and internationally. The company was incorporated in 1992 and is headquartered in Orlando, Florida.